Dual anti-platelet therapy remains a cornerstone of the treatment for coronary artery disease. When choosing a second anti-platelet, ticagrelor remains a principal agent after the recent PLATO trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback